**Summary Report: Earnings Conference Call - Zoetis**

**Date:** [Insert Date of Call]

**Speakers:**
- Kristin Peck, CEO
- Glenn David, CFO

**Investment Stance: Overweight**

**Strategic Overview:**

As reflected in the recent earnings call, Zoetis continues to demonstrate exceptional operational resilience and financial performance despite the ongoing global challenges posed by the COVID-19 pandemic. The company has effectively navigated the complexities of the current market, showcasing robust growth particularly in the companion animal products sector. 

**Key Financial Metrics from Q3:**

- **Revenue:** $1.8 billion, an increase of 13% on a reported basis and 15% operationally year-over-year.
- **Adjusted Net Income:** $524 million, a rise of 15% on a reported basis and 20% operationally.
- **Earnings Per Share:** Adjusted diluted earnings per share increased operationally by 21%.
- **Gross Margin:** 69.6%, slightly down by 50 basis points due to FX impacts and manufacturing costs.
- **Operational Expenses:** Increased 9% operationally due to elevated advertising and promotional expenses.

**Performance Highlights:**

1. **Companion Animal Products:** Exhibited strong growth, up 20% operationally, driven by the parasiticides portfolio including products like Simparica Trio, Revolution Plus, and key dermatology products like Cytopoint and Apoquel.

2. **Livestock Products:** Reported a 9% increase operationally, with notable performance in the U.S. cattle and China swine markets.

3. **R&D and Innovation:** Continued progress in R&D, with significant developments in pain management for pets, specifically through monoclonal antibodies which represent a promising new therapeutic avenue.

4. **International Markets:** Demonstrated robust growth of 11% operationally, with companion animal revenue growing by 20% operationally. The growth was notable in key markets such as the EU and China, with innovative launches and increased adoption of leading products like Simparica and Cytopoint.

5. **Upcoming Prospects:** Approval and anticipated launch of Librela in Europe, a new monoclonal antibody for osteoarthritis in dogs, showcases the company's commitment to innovation and market expansion.

**Market Outlook and Guidance:**

Zoetis has raised its full-year 2020 revenue guidance to between $6.55 billion and $6.625 billion, reflecting operational revenue growth of 7% to 8%. Adjusted net income is expected to be between $1.79 billion and $1.825 billion, translating into a 6% to 8% operational growth.

The company anticipates a slowdown in the livestock segment in Q4 due to seasonal buying patterns and ongoing challenges in the sector due to the pandemic. However, the overall business outlook remains strong due to the resilient demand in the companion animal sector and effective strategic initiatives.

**Conclusion and Investment Rationale:**

The adoption of an 'overweight' investment stance on Zoetis is supported by the company's robust financial performance, strategic market expansions, solid pipeline of innovative products, and the growing demand in the companion animal products market. Zoetis's strong operational execution, strategic cost management, and lucrative market positioning underline its capability to deliver sustained growth and shareholder value in a challenging economic landscape.

Investors are recommended to consider Zoetis for its strong market leadership, innovative R&D capabilities, and consistent financial performance which align with long-term growth prospects in the animal health industry.